Joshua Schultz - PAREXEL International President

<div class='circular--portrait' style='background:#000000;color: white;font-size:3em;padding-top: 25px;;'>PRX</div>
  President
Mr. Joshua Schultz is Senior Vice PresidentWorldwide Head of PAREXEL Access of the Company. He is responsible for leadership and oversight of all latestage clinical research, access consulting, drug safety and medical communications activities at the Company. From July 2015 to August 2016, he served as Corporationrationrate Vice President and Worldwide Head of PAREXEL Access. From January 2014 to July 2015, he served as Corporationrationrate Vice President and Worldwide Head of PeriPost Approval Clinical Excellence. From July 2009 to January 2014, he served as Corporationrationrate Vice President, Strategic Partnerships. Prior to joining PAREXEL, he served as Vice President of Corporationrationrate Development at Veritas Medicine, a developer of an online compliance system for clinical data disclosure. Previously, he worked at Mercer Management Consulting, where he developed growth strategies for Fortune 500 companies
Age: 41  President Since 2016      
781 487-9900  http://www.parexel.com
Schultz holds a Master of Philosophy degree in International Relations from the University of Cambridge, U.K. He also holds a BS in Economics degree from the Wharton School of Business and a Bachelor of Arts degree in International Relations from the University of Pennsylvania.

Management Efficiency

The company has return on total asset (ROA) of 4.71 % which means that it generated profit of $4.71 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 15.1 % meaning that it created $15.1 on every $100 dollars invested by stockholders.
The company currently holds 671.5 M in liabilities with Debt to Equity (D/E) ratio of 105.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has Current Ratio of 1.42 which is within standard range for the sector.

Similar Executives

Showing few of many executives

PRESIDENT Since

Joseph LaRosaRegeneron Pharmaceuticals
2019
Saumen ChakrabortyDr Reddys Laboratories Ltd
2018
Douglas BoothePerrigo Company Plc
2013
Charles WagnerVertex Pharmaceuticals Incorpor
2019
Roxanne LaganoZoetis
2015
Sandra BeatyZoetis
2012
Thomas FarringtonPerrigo Company Plc
2015
Peter PowchikRegeneron Pharmaceuticals
2006
Douglas McCorkleRegeneron Pharmaceuticals
2007
Christopher FenimoreRegeneron Pharmaceuticals
2017
Daniel PlewRegeneron Pharmaceuticals
2016
Michael StewartPerrigo Company Plc
2004
Joyce LeeZoetis
2012
Catherine KnuppZoetis
2012
Glenn DavidZoetis
2016
Andrew FentonZoetis
2018
Ronald JanishPerrigo Company Plc
2015
Louis YuPerrigo Company Plc
2013
Samiran DasDr Reddys Laboratories Ltd
2016
Jay MarkowitzRegeneron Pharmaceuticals
2017
Kimberly WhiteVertex Pharmaceuticals Incorpor
2018

Entity Summary

PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corp (PRXL) is traded on NASDAQ in USA and employs 18,600 people.

PAREXEL International Leadership Team

Michelle Graham, Chief Human Resource Officer, Senior Vice President
Ulf Schneider, Chief Administrative Officer, Senior Vice President
Thomas Senderovitz, Senior Vice President - Clinical Research Services
Dana Callow, Presiding Independent Director
Emma Reeve, Interim CFO, Corporate Vice President Controller
Josef Rickenbach, Founder, Chairman and CEO
Patrick Fortune, Independent Director
Eduard Holdener, Independent Director
Simon Harford, CFO, Senior Vice President
Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access
Gadi Saarony, Senior Vice President - Clinical Research Services
Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center
Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting
Xavier Flinois, President - Perceptive Informatics
Douglas Batt, Sr. VP, General Counsel and Secretary
Sybrand Pretorius, Senior Vice President Chief Scientific Officer
Maykin Ho, Director
Richard Love, Independent Director
Ronald Aldridge, Sr. Director, Investor Relations
Mark Goldberg, President COO
Roland Andersson, Senior Vice President - Clinical Research Services
Christopher Lindop, Independent Director
Ingo Bank, CFO and Sr. VP
David Godwin, Senior Vice President-Global Business

Stock Performance Indicators

Return On Equity15.10
Return On Asset4.71
window.location = "/error404.html";